Pharmaceuticals, Biotechnology and Life Sciences
European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.
BD (Becton, Dickinson and Company) will acquire Bard, a medical technology company focused on vascular, urology, oncology and surgical specialty products for $24 billion and appoint Tom Polen as new president of BD.
Teva Pharmaceutical Industries on Thursday launched an asthma inhaler that will be the first direct competition to GlaxoSmithKline’s best-selling Advair.
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
ThromboGenics will pay preclinical milestone to Bicycle Therapeutics in connection with the advancement of a Bicycle (bicyclic peptide) into preclinical development for the treatment of diabetic macular edema.
Diplomat Pharmacy will distribute Zejula (niraparib) for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Redx Pharma has a new Chairman of the Board of Directors and a Non-Executive Director of the company.
Oxford BioDynamics and its scientific advisory panel member, Dr Claudio Carini will be joining Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees, the company said Thursday.
A study showed that cannabidiol shows great promise in that it may reduce seizures that are otherwise difficult to control.